Cargando…

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

The mammalian target of rapamycin (mTOR) regulates cell growth and survival by integrating nutrient and hormonal signals. These signaling functions are distributed between at least two distinct mTOR protein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to the selective inhibitor rapamycin and ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldman, Morris E, Apsel, Beth, Uotila, Aino, Loewith, Robbie, Knight, Zachary A, Ruggero, Davide, Shokat, Kevan M
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637922/
https://www.ncbi.nlm.nih.gov/pubmed/19209957
http://dx.doi.org/10.1371/journal.pbio.1000038
_version_ 1782164381770973184
author Feldman, Morris E
Apsel, Beth
Uotila, Aino
Loewith, Robbie
Knight, Zachary A
Ruggero, Davide
Shokat, Kevan M
author_facet Feldman, Morris E
Apsel, Beth
Uotila, Aino
Loewith, Robbie
Knight, Zachary A
Ruggero, Davide
Shokat, Kevan M
author_sort Feldman, Morris E
collection PubMed
description The mammalian target of rapamycin (mTOR) regulates cell growth and survival by integrating nutrient and hormonal signals. These signaling functions are distributed between at least two distinct mTOR protein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to the selective inhibitor rapamycin and activated by growth factor stimulation via the canonical phosphoinositide 3-kinase (PI3K)→Akt→mTOR pathway. Activated mTORC1 kinase up-regulates protein synthesis by phosphorylating key regulators of mRNA translation. By contrast, mTORC2 is resistant to rapamycin. Genetic studies have suggested that mTORC2 may phosphorylate Akt at S473, one of two phosphorylation sites required for Akt activation; this has been controversial, in part because RNA interference and gene knockouts produce distinct Akt phospho-isoforms. The central role of mTOR in controlling key cellular growth and survival pathways has sparked interest in discovering mTOR inhibitors that bind to the ATP site and therefore target both mTORC2 and mTORC1. We investigated mTOR signaling in cells and animals with two novel and specific mTOR kinase domain inhibitors (TORKinibs). Unlike rapamycin, these TORKinibs (PP242 and PP30) inhibit mTORC2, and we use them to show that pharmacological inhibition of mTOR blocks the phosphorylation of Akt at S473 and prevents its full activation. Furthermore, we show that TORKinibs inhibit proliferation of primary cells more completely than rapamycin. Surprisingly, we find that mTORC2 is not the basis for this enhanced activity, and we show that the TORKinib PP242 is a more effective mTORC1 inhibitor than rapamycin. Importantly, at the molecular level, PP242 inhibits cap-dependent translation under conditions in which rapamycin has no effect. Our findings identify new functional features of mTORC1 that are resistant to rapamycin but are effectively targeted by TORKinibs. These potent new pharmacological agents complement rapamycin in the study of mTOR and its role in normal physiology and human disease.
format Text
id pubmed-2637922
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-26379222009-03-07 Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 Feldman, Morris E Apsel, Beth Uotila, Aino Loewith, Robbie Knight, Zachary A Ruggero, Davide Shokat, Kevan M PLoS Biol Research Article The mammalian target of rapamycin (mTOR) regulates cell growth and survival by integrating nutrient and hormonal signals. These signaling functions are distributed between at least two distinct mTOR protein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to the selective inhibitor rapamycin and activated by growth factor stimulation via the canonical phosphoinositide 3-kinase (PI3K)→Akt→mTOR pathway. Activated mTORC1 kinase up-regulates protein synthesis by phosphorylating key regulators of mRNA translation. By contrast, mTORC2 is resistant to rapamycin. Genetic studies have suggested that mTORC2 may phosphorylate Akt at S473, one of two phosphorylation sites required for Akt activation; this has been controversial, in part because RNA interference and gene knockouts produce distinct Akt phospho-isoforms. The central role of mTOR in controlling key cellular growth and survival pathways has sparked interest in discovering mTOR inhibitors that bind to the ATP site and therefore target both mTORC2 and mTORC1. We investigated mTOR signaling in cells and animals with two novel and specific mTOR kinase domain inhibitors (TORKinibs). Unlike rapamycin, these TORKinibs (PP242 and PP30) inhibit mTORC2, and we use them to show that pharmacological inhibition of mTOR blocks the phosphorylation of Akt at S473 and prevents its full activation. Furthermore, we show that TORKinibs inhibit proliferation of primary cells more completely than rapamycin. Surprisingly, we find that mTORC2 is not the basis for this enhanced activity, and we show that the TORKinib PP242 is a more effective mTORC1 inhibitor than rapamycin. Importantly, at the molecular level, PP242 inhibits cap-dependent translation under conditions in which rapamycin has no effect. Our findings identify new functional features of mTORC1 that are resistant to rapamycin but are effectively targeted by TORKinibs. These potent new pharmacological agents complement rapamycin in the study of mTOR and its role in normal physiology and human disease. Public Library of Science 2009-02 2009-02-10 /pmc/articles/PMC2637922/ /pubmed/19209957 http://dx.doi.org/10.1371/journal.pbio.1000038 Text en © 2009 Feldman et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Feldman, Morris E
Apsel, Beth
Uotila, Aino
Loewith, Robbie
Knight, Zachary A
Ruggero, Davide
Shokat, Kevan M
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
title Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
title_full Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
title_fullStr Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
title_full_unstemmed Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
title_short Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
title_sort active-site inhibitors of mtor target rapamycin-resistant outputs of mtorc1 and mtorc2
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637922/
https://www.ncbi.nlm.nih.gov/pubmed/19209957
http://dx.doi.org/10.1371/journal.pbio.1000038
work_keys_str_mv AT feldmanmorrise activesiteinhibitorsofmtortargetrapamycinresistantoutputsofmtorc1andmtorc2
AT apselbeth activesiteinhibitorsofmtortargetrapamycinresistantoutputsofmtorc1andmtorc2
AT uotilaaino activesiteinhibitorsofmtortargetrapamycinresistantoutputsofmtorc1andmtorc2
AT loewithrobbie activesiteinhibitorsofmtortargetrapamycinresistantoutputsofmtorc1andmtorc2
AT knightzacharya activesiteinhibitorsofmtortargetrapamycinresistantoutputsofmtorc1andmtorc2
AT ruggerodavide activesiteinhibitorsofmtortargetrapamycinresistantoutputsofmtorc1andmtorc2
AT shokatkevanm activesiteinhibitorsofmtortargetrapamycinresistantoutputsofmtorc1andmtorc2